Regulatory actions won’t stop growth of emerging markets, says Sanofi EVP Industry-The Economic Times — November 27, 2017 comments off Emerging markets account for 7% of Sanofi’s global revenues, driven by its limited product in rare diseases, diabetes and oncology segments.
Emerging markets account for 7% of Sanofi’s global revenues, driven by its limited product in rare diseases, diabetes and oncology segments.